Autoimmunity and graves disease

R. S. Bahn

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Current treatment options for Graves hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid-stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small-molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions.

Original languageEnglish (US)
Pages (from-to)577-579
Number of pages3
JournalClinical Pharmacology and Therapeutics
Volume91
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Graves Disease
Autoimmunity
Hormone Antagonists
Thyrotropin Receptors
Biological Therapy
Blocking Antibodies
Hyperthyroidism
Therapeutics
Monoclonal Antibodies
Ligands

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Autoimmunity and graves disease. / Bahn, R. S.

In: Clinical Pharmacology and Therapeutics, Vol. 91, No. 4, 04.2012, p. 577-579.

Research output: Contribution to journalArticle

Bahn, R. S. / Autoimmunity and graves disease. In: Clinical Pharmacology and Therapeutics. 2012 ; Vol. 91, No. 4. pp. 577-579.
@article{d39158ad1c15442d8cdfe2e1bf566314,
title = "Autoimmunity and graves disease",
abstract = "Current treatment options for Graves hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid-stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small-molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions.",
author = "Bahn, {R. S.}",
year = "2012",
month = "4",
doi = "10.1038/clpt.2012.10",
language = "English (US)",
volume = "91",
pages = "577--579",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Autoimmunity and graves disease

AU - Bahn, R. S.

PY - 2012/4

Y1 - 2012/4

N2 - Current treatment options for Graves hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid-stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small-molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions.

AB - Current treatment options for Graves hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid-stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small-molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions.

UR - http://www.scopus.com/inward/record.url?scp=84858759743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858759743&partnerID=8YFLogxK

U2 - 10.1038/clpt.2012.10

DO - 10.1038/clpt.2012.10

M3 - Article

C2 - 22434030

AN - SCOPUS:84858759743

VL - 91

SP - 577

EP - 579

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -